Academic Journal
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
| العنوان: | First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes |
|---|---|
| المؤلفون: | David Lang, Linda Ritzberger, Vanessa Rambousek, Andreas Horner, Romana Wass, Kaveh Akbari, Bernhard Kaiser, Jürgen Kronbichler, Bernd Lamprecht, Michael Gabriel |
| المصدر: | Cancers; Volume 13; Issue 23; Pages: 6096 |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute |
| سنة النشر: | 2021 |
| المجموعة: | MDPI Open Access Publishing |
| مصطلحات موضوعية: | total metabolic tumor volume, bone marrow to liver ratio, PET/CT, overall survival, immunotherapy, immune checkpoint inhibitor, standardized uptake value, response prediction |
| الوصف: | Quantitative biomarkers derived from positron-emission tomography/computed tomography (PET/CT) have been suggested as prognostic variables in immune-checkpoint inhibitor (ICI) treated non-small cell lung cancer (NSCLC). As such, data for first-line ICI therapy and especially for chemotherapy–ICI combinations are still scarce, we retrospectively evaluated baseline 18F-FDG-PET/CT of 85 consecutive patients receiving first-line pembrolizumab with chemotherapy (n = 70) or as monotherapy (n = 15). Maximum and mean standardized uptake value, total metabolic tumor volume (MTV), total lesion glycolysis, bone marrow-/and spleen to liver ratio (BLR/SLR) were calculated. Kaplan–Meier analyses and Cox regression models were used to assess progression-free/overall survival (PFS/OS) and their determinant variables. Median follow-up was 12 months (M; 95% confidence interval 10–14). Multivariate selection for PFS/OS revealed MTV as most relevant PET/CT biomarker (p < 0.001). Median PFS/OS were significantly longer in patients with MTV ≤ 70 mL vs. >70 mL (PFS: 10 M (4–16) vs. 4 M (3–5), p = 0.001; OS: not reached vs. 10 M (5–15), p = 0.004). Disease control rate was 81% vs. 53% for MTV ≤/> 70 mL (p = 0.007). BLR ≤ 1.06 vs. >1.06 was associated with better outcomes (PFS: 8 M (4–13) vs. 4 M (3–6), p = 0.034; OS: 19 M (12-/) vs. 6 M (4–12), p = 0.005). In patients with MTV > 70 mL, concomitant BLR ≤ 1.06 indicated a better prognosis. Higher MTV is associated with inferior PFS/OS in first-line ICI-treated NSCLC, with BLR allowing additional risk stratification. |
| نوع الوثيقة: | text |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | Cancer Therapy; https://dx.doi.org/10.3390/cancers13236096 |
| DOI: | 10.3390/cancers13236096 |
| الاتاحة: | https://doi.org/10.3390/cancers13236096 |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.57F8D7EB |
| قاعدة البيانات: | BASE |
كن أول من يترك تعليقا!